PBR Nachrichten

 

Importantly, the final trial results have also confirmed the drug's positive effects on the secondary trial endpoints that assessed the drug's activity and efficacy including measuring the effects The post Antisense ATL1102 final phase 2 DMD resul...

The Canadian biopharma company expects to immediately begin recruitment for the mid-stage trial of favipiravir with an aim to enroll nearly 760 subjects from both residents and staff The post Appili set to evaluate favipiravir as preventive measure ...

Nautilus' total funding now exceeds $100 million. The Nautilus platform will deliver single-molecule sensitivity more quickly, more completely, and less expensively than is possible with existing technologies. This The post Nautilus Biotechnology r...

The approval enables to use of Kynmobi sublingual film for the acute and intermittent treatment of off episodes in patients with Parkinson's disease. Kynmobi, a novel formulation of The post Sunovion gets FDA nod for Kynmobi to treat Parkinson's d...

Filgotinib 200 mg achieved all primary endpoints in the study, inducing clinical remission at Week 10 and maintaining clinical remission at Week 58 in a significantly higher proportion The post Gilead and Galapagos announce positive topline results ...

The approval by the US Food and Drug Administration (FDA) was based on results from the Phase III PROfound trial, which were published in the New England Journal The post LYNPARZA approved in US for HRR gene-mutated metastatic castration-resistant p...

Octagam 10% is an immune globulin intravenous (human) liquid preparation designated to treat chronic immune thrombocytopenic purpura (ITP) in adults. According to the company, the primary objective of The post FDA approves Octapharma USA's IND appl...

Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation. Investigators assessed efficacy using overall response rate (ORR) per The post Janssen announces phase 1...

According to Rallybio, new investors who took part in the funding round included Viking Global Investors, TPG's The Rise Fund, funds managed by Tekla Capital Management, F-Prime Capital, The post Rallybio raises $145m in Series B round for developi...

Under this IND, Tolero intends to conduct a Phase 1/1b, first-in-human, open-label, dose‑escalation, safety, pharmacokinetic and pharmacodynamic study, which will evaluate oral TP‑1454 alone, and in combination with The post Tolero Pharmaceutica...

The approval allows Zolgensma to treat patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1or patients with The post Novartis firm AveXis gets EC nod for Zolgensma to treat spinal muscular atrophy a...

“We are pleased to offer people with certain types of lung cancer a new chemotherapy-free option that can help prolong their lives and be administered on a flexible The post FDA approves Genentech's Tecentriq as first-line monotherapy for certain...

The company has reported positive interim clinical data of mRNA-1273 from the phase 1 study by the National Institute of Allergy and Infectious Diseases (NIAID), part of the The post Moderna's Covid-19 vaccine shows significant effect in early huma...

Can-Fite BioPharma, a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has filed a pre-Investigational New The post Can-Fite announces pre-IND sub...

The FDA approval allows Qinlock, a kinase inhibitor, to treat adult patients with advanced GIST who have secured prior treatment with three or more kinase inhibitors, including imatinib. The post Deciphera gets FDA nod for Qinlock to treat fourth-li...

Four metastatic pancreatic cancer patients have been treated with PD-L1 t-haNK and N-803 under single patient INDs, with two patients on treatment for an evaluable period. One patient reported The post NantKwest and ImmunityBio to initiate a phase ...

FDA Fast Track is a program designed to facilitate and expedite the development and review of a new drugs that demonstrates the potential to address an unmet medical The post Neuraptive Therapeutics announces FDA has granted fast track designation t...

Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) that includes an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent monomethyl auristatin E (MMAE) The post Takeda gets expanded ...

This agreement is part of Cipla’s efforts to enhance global access to life-saving treatments for patients affected by the pandemic. As part of the agreement, Cipla will be The post Cipla enters into a licensing agreement with Gilead to expand acce...

GA is a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration (AMD) for which there is no current treatment. Together, with Boehringer Ingelheim's expertise The post Boehringer Ingelheim collaborate...